ID   MDA-T41
AC   CVCL_W914
DR   ATCC; CRL-3352
DR   cancercelllines; CVCL_W914
DR   Cosmic; 2054114
DR   Cosmic; 2612755
DR   Wikidata; Q54904661
RX   PubMed=23833040;
RX   PubMed=25427145;
RX   PubMed=30737244;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=25427145; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ile831Phe (c.2491A>T); Zygosity=Heterozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe19fs (c.56_65delTTTCAGACCT); Zygosity=Heterozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Heterozygous (PubMed=30737244).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): ATCC=CRL-3352; PubMed=25427145; PubMed=30737244
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 9,12
ST   D16S539: 12
ST   D5S818: 9,12
ST   D7S820: 8,12
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 15,16
DI   NCIt; C4035; Thyroid gland papillary carcinoma
DI   ORDO; Orphanet_146; Differentiated thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   74Y
CA   Cancer cell line
DT   Created: 17-07-14; Last updated: 02-05-24; Version: 16
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=25427145; DOI=10.1210/jc.2014-2624;
RA   Henderson Y.C., Ahn S.-H., Ryu J., Chen Y.-Y., Williams M.D.,
RA   El-Naggar A.K., Gagea M., Schweppe R.E., Haugen B.R., Lai S.Y.,
RA   Clayman G.L.;
RT   "Development and characterization of six new human papillary thyroid
RT   carcinoma cell lines.";
RL   J. Clin. Endocrinol. Metab. 100:E243-E252(2015).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//